Search Results

Sequana Medical NV announces data from its North American pivotal POSEIDON study of the alfapump® demonstrating significantly improved quality of life focused on ascites symptoms and physical functions compared to baseline, which is not seen in refractory ascites patients enrolled contemporaneously in the prospective NACSELD3 cohort.

June 6, 2024

·

8 min read

Policy

Press news: Sequana Medical announces positive outcome of Day 100 meeting with FDA regarding PMA application for alfapump®

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces the agreed outcome of the “Day 100” meetingi with the US Food and Drug Administration, following receipt of the “Day 90” major deficiency Letter.

May 22, 2024

·

8 min read

Business

Sequana Medical announces 2023 Full Year Results and 2024 Outlook

Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.

March 28, 2024

·

21 min read

Press Releases

Press release: Sequana Medical Announces Key Opinion Leader (KOL) Webinar to Discuss alfapump® US Commercial Roll-Out on January 8th at 15:00 CET / 09:00 EST

January 6, 2025

·

10 min read

Press Releases

Press Release: Publication in Kidney Medicine Highlights Benefits of DSR 2.0 for Sequana Medical’s Direct Sodium Removal Heart Failure Program and Board Composition Update

November 27, 2024

·

8 min read